Previous 10 | Next 10 |
Syndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update PR Newswire – Topline data from revumenib (SNDX-5613) and axatilimab pivotal programs expected starting in 1H23; Company remains on track for two FDA fi...
ADES, AGM, AIV, AKBA, ALCO, ALTO, AMC, AMPH, AMWL, ANGI, APPF, APTO, ARCT, AROC, ASLE, ASRT, ATER, AVIR, AZTA, BATL, BHF, BLFS, BLI, BLNK, BODY, OTCPK:BOWFF, BRMK, BRT, BW, BWXT, CAPL, CARA, CARG, CHMI, CLAR, CLOV, CNNE, CSTL, OTCPK:CURLF, DDD, DHT, DNB, ENTA, EQH, EVBG, FCRD, FF, FGEN, FLL, ...
Syndax to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 9, 2022 PR Newswire WALTHAM, Mass. , May 2, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-...
Gainers: Super Micro Computer (SMCI) +14%. Luminar Technologies (LAZR) +5%. Veeco Instruments (VECO) +5%. CytomX Therapeutics (CTMX) +5%. Syndax Pharmaceuticals (SNDX) +5%. Losers: NETGEAR (NTGR) -11%. Lakeland Industries (LAKE) -9%. ACADIA Pharmaceuticals ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Advanced Micro Devices (NASDAQ: AMD ): A former penny stock that turned insanely profitable, became a $100 stock in less than five years BBQ Holdings (NASDAQ: BBQ ): Stock rose from $1.65 per share lows to ne...
Today's $19 share quote is backed by as much as $7.50 in cash vs. total liabilities under $1 per unit. Larger drug trials are underway testing the usefulness of two cancer-related products. Strong technical momentum trends have been building since December. For further detai...
The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with this event. For further details see: Syndax Pharmaceuticals (SNDX) Presents At Barclays Global Healthcare Conference
Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass. , March 4, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical compa...
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2021 Earnings Conference Call March 1, 2022 4:30 PM ET Company Participants Maghan Meyers - Vice President, Argot Partners Michael Metzger - Chief Executive Officer Alexander Nolte - Chief Accounting Officer Anjali Ganguli - Chief Business Officer Briggs...
The clinical-stage biotech, Syndax Pharmaceuticals (NASDAQ:SNDX), announced on Tuesday that Kate Madigan, M.D., will be appointed as the company’s new Chief Medical Officer, effective immediately. She will replace Michael Meyers, who will remain with the company until June before takin...
News, Short Squeeze, Breakout and More Instantly...
Syndax Pharmaceuticals Inc. Company Name:
SNDX Stock Symbol:
NASDAQ Market:
Syndax Pharmaceuticals Inc. Website:
Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024 PR Newswire WALTHAM, Mass. , July 25, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing...
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal myeloid cells, which are immature blood cells that normally...
Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress PR Newswire - Data continue to support revumenib's potential to enhance current standard of care agents - ...